中科微点-全球专利检索

  1. Login
  2. Sign Up
Invention Publication
CN110121345A 利用基于MYC癌基因过表达的合成致死的方法 有权 转让

  • Patent Title: 利用基于MYC癌基因过表达的合成致死的方法
  • Patent Title (English): PROCESS FOR EXPLOITING SYNTHETIC LETHALITY BASED ON OVEREXPRESSION OF MYC ONCOGENE
  • Application No.: CN201880005258.7
    Application Date: 2018-06-04
  • Publication No.: CN110121345A
    Publication Date: 2019-08-13
  • Inventor: 杨顿 , 张晶 , 张申秋
  • Applicant: 杨顿
  • Applicant Address: 美国加利福尼亚
  • Assignee: 杨顿
  • Current Assignee: 成都安泰康赛生物科技有限公司
  • Current Assignee Address: 美国加利福尼亚
  • Agency: 泰和泰律师事务所
  • Agent 曾祥坤; 刘梦菲
  • Priority: 62/514,861 2017.06.04 US
  • International Application: PCT/US2018/035907 2018.06.04
  • International Announcement: WO2018/226603 EN 2018.12.13
  • Date entered country: 2019-07-03
  • Main IPC: A61K31/505
  • IPC: A61K31/505 ;  A61K31/551
利用基于MYC癌基因过表达的合成致死的方法
Abstract:
本发明普适性涉及抑制剂化合物及其选择性杀伤一类癌细胞的用途。本文提供了与使用Rho相关蛋白激酶抑制剂例如二甲基法舒地尔治疗过表达MYC癌基因家族的癌症相关的方法和手段，其已显示引起细胞凋亡。
Abstract(English):

The present invention generally relates to inhibitor compounds and their use to selectively kill a class of cancer cells. Methods and means related to the treatment of cancers which overexpress the MYC family of oncogenes using Rho-associated protein kinase inhibitors, such as dimethylfasudil, which have shown to elicit cellular apoptosis, are provided herein.

Public/Granted literature
Patent Agency Ranking
0/0